{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermittent+Dosing+of+Medication", "query": { "intervention": "Intermittent Dosing of Medication" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermittent+Dosing+of+Medication&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T15:17:29.964Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06658093", "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Aging" ], "interventions": [ { "name": "Rapamycin", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "65 Years to 90 Years" }, "enrollment_count": 194, "start_date": "2026-03-04", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-16T15:17:29.964Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06658093" }, { "nct_id": "NCT04040452", "title": "Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Congenital Heart Disease in Children" ], "interventions": [ { "name": "Continuous ketorolac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phoenix Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "59 Months", "sex": "ALL", "summary": "3 Months to 59 Months" }, "enrollment_count": 166, "start_date": "2021-03-01", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-16T15:17:29.964Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04040452" }, { "nct_id": "NCT06954129", "title": "A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Kidney Injury" ], "interventions": [ { "name": "Vancomycin", "type": "DRUG" }, { "name": "Piperacillin-tazobactam", "type": "DRUG" }, { "name": "Cefepime", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2026-01-28", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-16T15:17:29.964Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06954129" }, { "nct_id": "NCT03435003", "title": "Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Post-operative Nausea and Vomiting", "Laparoscopic Sleeve Gastrectomy" ], "interventions": [ { "name": "Aprepitant 80 mg Oral Capsule", "type": "DRUG" }, { "name": "scopolamine transdermal", "type": "DRUG" }, { "name": "Total intravenous anesthesia", "type": "PROCEDURE" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Reglan", "type": "DRUG" }, { "name": "Compazine", "type": "DRUG" }, { "name": "Sugammadex", "type": "DRUG" }, { "name": "Propofol", "type": "DRUG" }, { "name": "dexmedetomidine", "type": "DRUG" }, { "name": "Fentanyl", "type": "DRUG" }, { "name": "Sevoflurane", "type": "DRUG" }, { "name": "Desflurane", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Stony Brook University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2017-08-28", "completion_date": "2019-04-01", "has_results": true, "last_update_posted_date": "2024-02-14", "last_synced_at": "2026-09-16T15:17:29.964Z", "location_count": 1, "location_summary": "Stony Brook, New York", "locations": [ { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435003" }, { "nct_id": "NCT01703481", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor or Lymphoma" ], "interventions": [ { "name": "JNJ-42756493: Part 1", "type": "DRUG" }, { "name": "JNJ-42756493: Part 2", "type": "DRUG" }, { "name": "JNJ-42756493: Part 3", "type": "DRUG" }, { "name": "JNJ-42756493: Part 4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 188, "start_date": "2012-06-15", "completion_date": "2017-07-05", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-09-16T15:17:29.964Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01703481" }, { "nct_id": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Vistusertib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cediranib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 528, "start_date": "2017-12-18", "completion_date": "2026-09-11", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-09-16T15:17:29.964Z", "location_count": 17, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334617" }, { "nct_id": "NCT00364780", "title": "Study of XL647 in Subjects With Non-Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small-cell Lung Cancer" ], "interventions": [ { "name": "XL647", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kadmon Corporation, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2006-07", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2022-05-13", "last_synced_at": "2026-09-16T15:17:29.964Z", "location_count": 7, "location_summary": "Port Saint Lucie, Florida • Chicago, Illinois • Urbana, Illinois + 4 more", "locations": [ { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00364780" }, { "nct_id": "NCT00283803", "title": "Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Exisulind", "type": "DRUG" }, { "name": "luteinizing hormone-releasing hormone (LHRH) agonist", "type": "DRUG" }, { "name": "Antiandrogen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "MALE", "summary": "21 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2002-03-12", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-09-16T15:17:29.964Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283803" }, { "nct_id": "NCT00414635", "title": "FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Intermitent Dosing", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Community Research Initiative of New England", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2006-08", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-09-16T15:17:29.964Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00414635" }, { "nct_id": "NCT05884398", "title": "A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castrate-sensitive Prostate Cancer" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Androgen-deprivation Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 420, "start_date": "2023-08-31", "completion_date": "2028-10-12", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-16T15:17:29.964Z", "location_count": 46, "location_summary": "Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05884398" } ] }